Anna Luisa Schaffgotsch

Impli is a medtech company developing the next generation of real-time molecular monitoring through minimally invasive implantable biosensors. Just as continuous glucose monitors (CGMs) transformed diabetes management by replacing episodic blood tests with continuous data streams, Impli’s platform extends this paradigm to a far broader range of hormones and biomarkers — unlocking an entirely new category of precision health data. Built on a proprietary aptamer-based biosensing platform with NFC wireless transmission, Impli’s technology captures molecular data continuously and non-disruptively via interstitial fluid. Where traditional diagnostics offer snapshots, Impli provides the full longitudinal picture, a continuous, high-resolution record of an individual’s molecular state over time. This data layer is where Impli’s platform becomes truly transformative. The rich, longitudinal biomarker datasets generated at scale represent a proprietary asset with applications that extend far beyond point-of-care diagnostics. In digital health, continuous molecular data is the missing foundation for credible human digital twins, dynamic, physiologically grounded models that can predict disease trajectories, simulate treatment responses, and personalise interventions at the individual level in ways that wearable or genomic data alone cannot support. For the pharmaceutical industry, the implications are equally profound. Impli’s platform offers a new window into drug pharmacodynamics and biomarker response in real-world, real-time conditions — accelerating clinical trial endpoints, enabling more precise patient stratification, and generating the kind of continuous biological evidence that static trial designs have historically been unable to capture. As the industry moves toward adaptive trials and biomarker-driven development, continuous molecular monitoring becomes a critical infrastructure layer. At a broader level, population-scale datasets of continuous hormonal and molecular data represent an entirely new class of health intelligence, with applications in early disease detection, longevity research, and the development of AI-driven diagnostic and therapeutic tools. Spun out of Imperial College London in 2022, Impli is backed by Boost VC, Lichtsteiner Foundation, and Dart Ventures, with commercial partnerships including Bayer and Ovation Fertility. The company was named Hello Tomorrow MedTech Startup of the Year 2025.